ANDA

Recent decline in case filings: Lex Machina ANDA Litigation

On Thursday, April 27th, legal data analytics firm Lex Machina released a Hatch-Waxman/ANDA litigation report detailing trends and key findings from pharmaceutical cases filed in U.S. district courts between January 1st, 2009, and March 31st, 2017. More than eight years worth of data shows that patent infringement case filings in response to abbreviated new drug applications (ANDAs) filed [...]

By |2017-09-07T17:57:10+05:30May 9th, 2017|International, IP Basics|0 Comments
Read More

FDA Approves Olmesartan Generics

As readers with even very little attachment to lawsuits on intersection of patent and FDA law would know that this drug product had been a subject of herculean tug o’ war between generic rivals- Mylan (Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices [...]

By |2017-09-08T13:39:14+05:30December 23rd, 2016|Patent|0 Comments
Read More
Go to Top